Scarica l'app Stockscreener
0.9777
1.03%
0.01
Dopo l'orario di chiusura:
1.00
0.0223
+2.28%
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip - Investing.com
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Form 8K Lucid Diagnostics Inc For: 13 August By Investing.com - Investing.com South Africa
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision - TipRanks
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics Q2 2026 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue - Quiver Quantitative
Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary - TradingView
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside - Yahoo Finance
Lucid Diagnostics at canaccord growth conference: reimbursement push builds By Investing.com - Investing.com Australia
Lucid Diagnostics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Enterprise value to EBIT forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to book forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to earnings forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Enterprise value to EBITDA forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Enterprise value to revenue forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Lucid Diagnostics Inc (LUCD) Stock News Today - TradingKey
Lucid Diagnostics (LUCD) Projected to Announce Quarterly Earnings on Thursday - marketbeat.com
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test - Bitget
Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria - Stock Titan
Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings - Stock Titan
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Yahoo Finance
Weekly Recap: Q2 2026 earnings call and EsoGuard/EsoCheck sales - TradingView
PAVmed CEO to update operations; CFO to discuss Q2 financial results Aug. 14 - Stock Titan
PAVmed to Host Business Update Conference Call on August 14 - Intellectia AI
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics schedules business update call to discuss Q2 2026 results - Bitget
LUCD|Lucid Diagnostics Inc|Price:0.904|Chg%:-0.003 - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):